[Substituted benzimidazoles--a new dimension in ulcer therapy?].
Substituted benzimidazoles represent a new class of gastric secretory inhibitors, which suppress acid secretion via direct inhibition of the parietal cell H+/K+-ATPase. The most potent derivative so far is omeprazole, which inhibits basal acid secretion and prevents the stimulatory effect of all classical acid secretory stimulants. In man, a single dose of 80 mg leads to almost complete achlorhydria over 24 hours. The results of the first duodenal ulcer trial with omeprazole are encouraging. No definite side effects have been attributed to the drug so far. Omeprazole may possibly initiate a new era in the medical treatment of peptic ulcer disease.
D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004942:Esophagitis, Peptic / Q000188:drug therapy; D006801:Humans; D006863:Hydrogen-Ion Concentration; D009853:Omeprazole; D010437:Peptic Ulcer / Q000188:drug therapy*; D010919:Placebos; D000254:Sodium-Potassium-Exchanging ATPase / Q000037:antagonists & inhibitors; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy
D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D010919:Placebos; D000254:Sodium-Potassium-Exchanging ATPase; D009853:Omeprazole
Substituierte Benzimidazole--eine neue Dimension der Ulkustherapie?